• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    5/28/24 12:31:12 PM ET
    $AKAN
    $APDN
    $CALT
    $GTHX
    Medicinal Chemicals and Botanical Products
    Health Care
    Other Consumer Services
    Consumer Discretionary
    Get the next $AKAN alert in real time by email

    Gainers

    • Sharps Technology (NASDAQ:STSS) stock rose 140.0% to $0.51 during Tuesday's regular session. The company's market cap stands at $8.0 million.
    • Insmed (NASDAQ:INSM) stock moved upwards by 112.72% to $46.8. The company's market cap stands at $6.9 billion.
    • Calliditas Therapeutics (NASDAQ:CALT) shares moved upwards by 69.26% to $37.95. The company's market cap stands at $1.0 billion. The company's, Q1 earnings came out 3 days ago.
    • Predictive Oncology (NASDAQ:POAI) shares rose 36.54% to $2.14. The company's market cap stands at $8.7 million.
    • Semler Scientific (NASDAQ:SMLR) stock moved upwards by 28.55% to $29.98. The company's market cap stands at $211.8 million.
    • Exicure (NASDAQ:XCUR) shares rose 23.02% to $0.41. The market value of their outstanding shares is at $3.5 million.

    Losers

    • Applied DNA Sciences (NASDAQ:APDN) stock decreased by 68.9% to $0.62 during Tuesday's regular session.
    • Innovative Eyewear (NASDAQ:LUCY) shares fell 39.58% to $0.59. The company's market cap stands at $10.3 million.
    • Summit Therapeutics (NASDAQ:SMMT) shares declined by 28.85% to $2.4. The market value of their outstanding shares is at $1.6 billion.
    • Akanda (NASDAQ:AKAN) shares declined by 18.5% to $3.35. The market value of their outstanding shares is at $3.0 million.
    • G1 Therapeutics (NASDAQ:GTHX) shares fell 17.85% to $3.36. The company's market cap stands at $175.6 million.
    • 60 Degrees (NASDAQ:SXTP) stock declined by 17.41% to $0.26. The market value of their outstanding shares is at $3.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $APDN
    $CALT
    $GTHX

    CompanyDatePrice TargetRatingAnalyst
    Insmed Incorporated
    $INSM
    1/28/2026$231.00Overweight
    Barclays
    Insmed Incorporated
    $INSM
    1/23/2026$212.00Buy
    Roth Capital
    Insmed Incorporated
    $INSM
    12/19/2025$202.00Buy
    Truist
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    Insmed Incorporated
    $INSM
    12/4/2025$263.00Buy
    Rothschild & Co Redburn
    Summit Therapeutics Inc.
    $SMMT
    11/18/2025Peer Perform
    Wolfe Research
    Insmed Incorporated
    $INSM
    10/28/2025$192.00Overweight
    Cantor Fitzgerald
    Insmed Incorporated
    $INSM
    10/20/2025$171.00Overweight
    Wells Fargo
    More analyst ratings

    $AKAN
    $APDN
    $CALT
    $GTHX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $1,562,328 worth of shares (10,699 units at $146.03) (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    3/5/26 4:16:51 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sharoky Melvin Md gifted 100 shares, decreasing direct ownership by 0.04% to 242,776 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    3/5/26 4:15:10 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sharoky Melvin Md gifted 1,072 shares and received a gift of 972 shares, decreasing direct ownership by 0.44% to 242,876 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    2/27/26 4:14:51 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $APDN
    $CALT
    $GTHX
    SEC Filings

    View All

    60 Degrees Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    3/12/26 4:36:53 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by 60 Degrees Pharmaceuticals Inc.

    424B5 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    3/11/26 5:25:24 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Insmed Incorporated

    144 - INSMED Inc (0001104506) (Subject)

    3/5/26 4:59:55 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $APDN
    $CALT
    $GTHX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-13) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/01/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    6/2/23 4:38:39 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-12) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    2/13/23 4:39:32 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

    Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/20/21 3:40:41 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $APDN
    $CALT
    $GTHX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

    All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publicationCompany calls for existing babesiosis treatment guidelines to be reviewed in light of the new data WASHINGTON, March 11, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three of three enrolled patients have been cured of babesiosis after completing the tafenoquine regimen in the Company's trial of relapsing babesiosis in immunosuppressed patients. The Com

    3/11/26 7:24:00 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., March 5, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 85 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.In connection with the commence

    3/5/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $APDN
    $CALT
    $GTHX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gross Harrison R. bought $1,980 worth of shares (1,500 units at $1.32), increasing direct ownership by 12% to 13,733 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/22/26 11:29:05 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Gayle Oswald bought $1,669 worth of shares (1,000 units at $1.67), increasing direct ownership by 54% to 2,865 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/15/26 5:00:07 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    $AKAN
    $APDN
    $CALT
    $GTHX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Insmed with a new price target

    Barclays initiated coverage of Insmed with a rating of Overweight and set a new price target of $231.00

    1/28/26 7:17:09 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Insmed with a new price target

    Roth Capital initiated coverage of Insmed with a rating of Buy and set a new price target of $212.00

    1/23/26 8:19:26 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist resumed coverage on Insmed with a new price target

    Truist resumed coverage of Insmed with a rating of Buy and set a new price target of $202.00

    12/19/25 8:48:21 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $APDN
    $CALT
    $GTHX
    Leadership Updates

    Live Leadership Updates

    View All

    Strive Announces the Completion of Semler Scientific Acquisition

    DALLAS, TX, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Strive, Inc. (NASDAQ:ASST) ("Strive") today announced the successful completion of the previously announced acquisition of Semler Scientific. Strive now holds approximately 12,797.9 bitcoin, becoming the #11 largest public corporate holder of bitcoin globally. Strive also announces the appointment of Avik Roy as Chief Strategy Officer of Strive. Mr. Roy's initial focus will be on Strive's intentions to monetize the operating business from the Semler Scientific subsidiary by expanding its mandate in early disease detection products.  Mr. Roy began his career in science at MIT and trained as a physician at Yale Medical School before joining Ba

    1/16/26 8:40:00 AM ET
    $ASST
    $SMLR
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy

    Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to democratize access to AI infrastructure, today announced additions to its leadership team and Board of Directors in support of the Company's new digital asset treasury strategy focused on the Aethir (ATH) token. The Company announced today that Shawn Matthews, CEO of

    10/14/25 8:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Strive, Inc. (Nasdaq: ASST) and Semler Scientific, Inc. (Nasdaq: SMLR) Announce Bitcoin Treasury Merger in All-Stock Transaction

    DALLAS, TX and CAMPBELL, CA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Strive, Inc. ("Strive") entered into a definitive agreement to acquire Semler Scientific, Inc. ("Semler Scientific") in an all-stock transaction. In addition, Strive announced the purchase of 5,816 Bitcoin to its corporate treasury at an average price of $116,047 per Bitcoin, for a total purchase price of $675,000,000, inclusive of fees and expenses, bringing Strive's total Bitcoin holdings to 5,886. Transaction details: Deal represents an approximately 210% premium, equivalent to approximately $90.52 per share, based on the trading price of Semler Scientific common stock and Strive Class A common stock as of the market clos

    9/22/25 8:15:00 AM ET
    $ASST
    $SMLR
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AKAN
    $APDN
    $CALT
    $GTHX
    Financials

    Live finance-specific insights

    View All

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

    HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed Phase III ILLUMINE Study in 1L PD-L1 Positive R/M HNSCC Sponsored by Cooperative Group, GORTEC, to Initiate; First Patient Expected in Early Q2 2026 US FDA Accepts BLA Filing Based on HARMONi Study; PDUFA Goal Action Date of November 14, 2026 First Patient Dosed in Revolution Medicines Clinical Trial Collaboration Evaluating Ivonescimab in Combination with RAS(ON) Inhibitors in RAS Mutant Tumors GSK Collaboration Clinical Trials Evaluating Ivonescimab in

    2/23/26 4:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update

    —Company Expects Full-Year 2026 BRINSUPRI® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE® (amikacin liposome inhalation suspension) Revenue Guidance of $450 Million to $470 Million——Total Company Revenues of $606.4 Million for Full-Year 2025——BRINSUPRI Total Revenues of $144.6 Million for Fourth-Quarter and $172.7 Million for Full-Year 2025——ARIKAYCE Total Revenues of $119.2 Million for Fourth-Quarter and $433.8 Million for Full-Year 2025, Representing 19% Annual Growth and Exceeding the Upper End of Full-Year 2025 Guidance——Topline Data Readouts from Phase 3 ENCORE and Phase 2b CEDAR Studies Remain on Track——FDA grants Orphan Drug Designation to Trepro

    2/19/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $APDN
    $CALT
    $GTHX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Semler Scientific Inc.

    SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)

    12/12/24 4:16:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Semler Scientific Inc.

    SC 13G - Semler Scientific, Inc. (0001554859) (Subject)

    11/26/24 12:09:40 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care